Global Navigation
- AZ’s UK research job losses ‘bad news’ for country’s industry say unions
GMB and Unite say 350 job cuts in R&D at Chesire facility will damage UK industry, although ABPI remains optimistic
- Victoza drives Novo Nordisk growth in 2011
Diabetes portfolio encourages 12 per cent increase in revenues for Denmark-based firm
- Merck returns to profit in Q4
Gains in diabetes division, but generics pose threat for 2012
- Mitchell Gold steps down as CEO and president of Dendreon
Former Savient CEO and Lilly senior VP John Johnson replaces Gold who remains at Dendreon as executive chair
- Caudex Medical makes senior hires
Appoints Andy Bowman and Gary Burd
- EMA prepares for major changes to European pharmacovigilance legislation
New measures will encourage greater transparency and allow patients in any European Member State to report adverse reactions
- Pfizer recalls contraceptive pills after packaging blunder
One million packages of Lo/Ovral-28, Norgestrel and Ethinyl Estradiol voluntarily withdrawn in US after mix-up leads to risk of unwanted pregnancy
- Personalised medicine for cystic fibrosis cleared in US
Vertex' 'breakthrough' Kalydeco is first treatment to target genetic mutation in the disease
- Abiraterone too expensive for NHS, says NICE
Price of J&J's prostate cancer treatment too high to justify use in UK
- AstraZeneca to cut 7,300 jobs in global restructuring
Sales, research and supply chain operations among those affected
- Income up for Roche despite dip in sales
Swiss firm looks to new products and purchase of Illumina to compensate for revenue decline
- Dan Zabrowski takes over as head of Roche Applied Science
Former global head of partnering succeeds Paul Brown
- Astellas, Medivation prostate cancer drug beats expectations in phase III
Results come as Astellas records net income increase of 24 per cent in the fiscal third quarter
- Generics take toll on Lilly’s 2011 financial results
Sales of antipsychotic Zyprexa fall 44 per cent in fourth quarter
- Pfizer lost $5bn to generics in 2011
Pharma giant’s fourth quarter hit particularly hard after Lipitor’s November US patent expiry
- European Commission drops Servier misinformation investigation
Charges part of wider anticompetitive behaviour case involving generic perindopril
- Napp hires Dietmar Leitner as managing director
Former general manager at Mundipharma succeeds Antony Mattessich
- European healthcare logistics association launched
EALTH will lobby for greater awareness of the health supply chain sector
- Pfizer in talks to sell Kent, UK research facility
Pharma firm confirms advanced discussions with property consortium for sale of Discovery Park
- SkyePharma's CEO Axel Mueller resigns
He will be replaced by the drug delivery company’s chief financial officer Peter Grant
Major pharma deals during 2011
Deal watch: A look at the biggest mergers and acquisitions from 2011, including Sanofi's purchase of Genzyme and J&J taking over Synthes
Pillars of success in market access
The key to true market access success begins with corporate ownership…
Proving value in uncertain times
Industry needs to be perceived as a contributor to healthcare solutions not just a cost
How to win through integrating market access
Embedding and integrating market access strategies company-wide is key
The role of systematic review in market access
Modern market access activities need to be evidence-based. But what does this really mean for new products being taken to market around the world?
Country Report: The healthcare market in Spain
Currently facing a major financial crisis, Spain's healthcare system is overstretched with autonomous regions owing millions of Euros to suppliers such as the pharma industry
Impact of cardiovascular events on diabetes treatment pipeline
Therapies are facing greater scrutiny to ensure they do not carry increased risk of cardiovascular side effects
Were healthcare ads really that good in the 1980s?
How centrally developed advertising campaigns can work in local markets and taking tips from motor industry campaigns can help increase brand engagement
Current and future challenges for market access in the UK
A survey of pharma companies shows they are hiring expert help to cope with the problems of an increasingly fragmented market in the UK
Become ‘patient intelligent’ to cure treatment aversion
Patients seldom refuse therapy outright, but often show a reluctance to comply. Understanding the reasons for this is the first step to improving their treatment
